| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1867 | |
| Phytochemical name or plant extracts | Conjugated linoleic acid | |
| PMID | 26434699 | |
| Literature evidence | CONCLUSIONS: This meta-analysis indicated that both dietary linoleic acid intake and serum linoleic acid level were associated with decreased risk of breast cancer, although none of the associations were statistically significant. | |
| IUPAC name | (9E,11E)-octadeca-9,11-dienoic acid | |
| Phytochemicals’ class or type of plant extracts | Polyunsaturated fatty acids | |
| Source of phytochemicals or plant Extracts | Agaricus bisporous,Momordica charantia | |
| Geographical availability | Europe and North America, Asia, Africa, and the Caribbean | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Bladder cancer, Liver cancer, Glioma, Prostate cancer, Colorectal cancer, Skin cancer | |
| Target gene or protein | LXR, PTPgamma, c-myc | |
| Gene or Protein evidence | Anti-proliferative and pro-apoptotic effects of the trans9, trans11 conjugated linoleic acid isomer on MCF-7 breast cancer cells - associated with LXR activation. The results indicate that dietary CLA might serve as a chemo-preventive and chemo-therapeutic agent in human breast cancers by up-regulating the estrogen-regulated tumor suppressor gene, PTPgamma expression. Inhibits expression of c-myc in MCF-7 cells | |
| Target pathways | ERK/MAPK pathway | |
| IC50 | NA | |
| Potency | Our results indicate that CLA can compete with PUFA and influence serum concentration of PUFA and their LOX metabolites, which could partly explain the anticancerogenic action of CLA. | |
| Cell line/ mice model | MDA-MB-231, MCF-7, SG652, 639V, ADF, PC3, LNCaP, SK-HEP-1, HepG2, MCF-7aro, MDA-wt, MDA-ERalpha7, M21-HPB, HT-29 | |
| Additional information | Exhibits inhibitory effect on the following cell lines: Breast MDA-MB-231, Breast MCF-7, Bladder SG652, Bladder 639V2, Glioblastoma ADF, Prostate PC3, Prostate LNCaP, Hepatoma SK-HEP-1, Hepatoma HepG2 (IN VIVO, IN NUDE MICE) Induction of apoptosis strongly in SK-HEP-1 hepatoma cells, ADF glioblastoma cells and moderately in LNCaP and PC3 cells and MCF-7 cells.(IN VIVO, IN NUDE MICE) Induction of necrosis in ADF glioblastoma cells, and PC3, LNCaP cells (200µm dose) Causes positive or negative variations in PPARs - increase of PPARalpha protein in cells undergoing strong induction of apoptosis - SK-HEP-1 hepatoma cells, ADF glioblastoma cells, decrease in PPARbeta/delta protein in SK-HEP-1 hepatoma cells, ADF glioblastoma cells, PC3, MCF-7 cells. (IN VIVO, IN NUDE MICE) Decreases mcf-7 human breast cancer cell growth and insulin-like growth factor-1 receptor levels Inhibits growth and [3H]thymidine incorporation of normal HMEC and MCF-7 cancer cells, CLA effects were mediated through lipoxygenase inhibition Induces apoptotic activity against estrogen receptor negative breast cancer cells. Inhibtion of aromatase in MCF-7aro cell line Decreases both tumor cell proliferation and tumor weight with no effect on rate of apoptosis. (IN NUDE MICE injected with MCF-7aro cells) Weak antiproliferative activity and 5% to 10% apoptosis of MDA-wt and MDA-ERalpha7 cells Selectively inhibits proliferation of ER positive MCF-7 cells, cells remain in the G0/G1 phase Causes significant reductions in proliferation (18-100%) of M21-HPB- malignant melanoma, HT-29 - colorectal and MCF-7- breast cancer cells. | |
| PubChem ID | 5282796 | |
| Additional PMIDs | 15316938 19266226 9066651 27509982 17178902 19789297 9215854 1562989 19800873 23375583 10810338 | |
| Additional sources of information | NA | |
| Safety | NA |